Shanxi Zhendong Pharmaceutical (300158) — Net Asset Quality Index
Shanxi Zhendong Pharmaceutical (300158) has a Net Asset Quality Index of 80.4% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥4.51 Billion minus total liabilities of CN¥882.65 Million yields net assets of CN¥3.63 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Read 300158 total liabilities for a breakdown of total debt and financial obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shanxi Zhendong Pharmaceutical Net Asset Quality Index Over Time (2007–2024)
This chart shows how Shanxi Zhendong Pharmaceutical's Net Asset Quality Index has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the index stands at 80.4%, representing net assets of CN¥3.63 Billion against total assets of CN¥4.51 Billion CNY. For live market cap and overall valuation, see Shanxi Zhendong Pharmaceutical (300158) total market value.
Annual Net Asset Quality Index for Shanxi Zhendong Pharmaceutical (2007–2024)
The table below presents the year-by-year Net Asset Quality Index for Shanxi Zhendong Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. Check how strategically is Shanxi Zhendong Pharmaceutical's equity deployed to assess the company's strategic physical and investment asset allocation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 73.5% | CN¥3.66 Billion | CN¥4.98 Billion | CN¥1.32 Billion | ▼ -9.8 pp |
| 2023 | 83.2% | CN¥5.14 Billion | CN¥6.18 Billion | CN¥1.04 Billion | ▲ +3.5 pp |
| 2022 | 79.7% | CN¥5.22 Billion | CN¥6.55 Billion | CN¥1.33 Billion | ▼ -0.1 pp |
| 2021 | 79.8% | CN¥8.05 Billion | CN¥10.09 Billion | CN¥2.04 Billion | ▲ +5.7 pp |
| 2020 | 74.1% | CN¥5.63 Billion | CN¥7.60 Billion | CN¥1.97 Billion | ▼ -4.6 pp |
| 2019 | 78.7% | CN¥5.44 Billion | CN¥6.92 Billion | CN¥1.47 Billion | ▲ +4.3 pp |
| 2018 | 74.3% | CN¥5.36 Billion | CN¥7.21 Billion | CN¥1.85 Billion | ▲ +1.3 pp |
| 2017 | 73.0% | CN¥5.56 Billion | CN¥7.61 Billion | CN¥2.06 Billion | ▼ -3.7 pp |
| 2016 | 76.7% | CN¥5.27 Billion | CN¥6.87 Billion | CN¥1.60 Billion | ▲ +26.8 pp |
| 2015 | 49.9% | CN¥2.03 Billion | CN¥4.07 Billion | CN¥2.04 Billion | ▼ -19.0 pp |
| 2014 | 68.9% | CN¥1.97 Billion | CN¥2.86 Billion | CN¥888.23 Million | ▼ -1.1 pp |
| 2013 | 70.0% | CN¥1.96 Billion | CN¥2.80 Billion | CN¥838.64 Million | ▼ -3.5 pp |
| 2012 | 73.5% | CN¥1.90 Billion | CN¥2.58 Billion | CN¥684.26 Million | ▼ -8.9 pp |
| 2011 | 82.4% | CN¥1.86 Billion | CN¥2.26 Billion | CN¥397.40 Million | ▲ +0.3 pp |
| 2010 | 82.1% | CN¥1.78 Billion | CN¥2.17 Billion | CN¥389.13 Million | ▲ +26.2 pp |
| 2009 | 55.9% | CN¥359.31 Million | CN¥643.18 Million | CN¥283.87 Million | ▲ +2.2 pp |
| 2008 | 53.7% | CN¥266.72 Million | CN¥496.69 Million | CN¥229.98 Million | ▲ +15.9 pp |
| 2007 | 37.8% | CN¥176.42 Million | CN¥466.70 Million | CN¥290.28 Million | — |